There is currently no direct evidence that combining two CGRP inhibitors can result in hypertension and increased risk of cardiovascular events, though it must be noted that the adverse effects mentioned may be a limiting factor when considering dual CGRP blockade. This evidence concerns the gene CALCA and Hypertension.